NYSEAMERICAN:ARMP Armata Pharmaceuticals (ARMP) Stock Price, News & Analysis $2.33 -0.07 (-2.92%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$2.27▼$2.4050-Day Range N/A52-Week Range$1.90▼$4.48Volume2,467 shsAverage Volume9,140 shsMarket Capitalization$84.30 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort Interest Get Armata Pharmaceuticals alerts: Email Address Armata Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside200.4% Upside$7.00 Price TargetShort InterestHealthy0.06% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.02) to ($1.57) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.25 out of 5 stars 3.5 Analyst's Opinion Consensus RatingArmata Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageArmata Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Armata Pharmaceuticals' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.06% of the float of Armata Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverArmata Pharmaceuticals has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Armata Pharmaceuticals has recently increased by 133.33%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldArmata Pharmaceuticals does not currently pay a dividend.Dividend GrowthArmata Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ARMP. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Armata Pharmaceuticals this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Armata Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Armata Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders85.50% of the stock of Armata Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 3.57% of the stock of Armata Pharmaceuticals is held by institutions.Read more about Armata Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Armata Pharmaceuticals are expected to decrease in the coming year, from ($1.02) to ($1.57) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Armata Pharmaceuticals is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Armata Pharmaceuticals is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm Press Fmr CIA Advisor reveals PEACEMAKER superweaponKamala cannot get the “codes” to this superweapon. In Trump’s hands, it will restore America’s global dominance. It could also help Americans struggling under Bidenomics by potentially sending 5 military stocks SOARING. Historically, similar stocks have shot up 16,270% in just 18 months.Full details are in this announcement. About Armata Pharmaceuticals Stock (NYSEAMERICAN:ARMP)Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.Read More ARMP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARMP Stock News HeadlinesSeptember 5 at 7:30 AM | prnewswire.comArmata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | ca.finance.yahoo.comTG1M.SG,0P00015OC5,0 (TG1M.SG)September 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.August 26, 2024 | prnewswire.comArmata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research SymposiumAugust 24, 2024 | money.usnews.comSilexion Therapeutics CorpAugust 15, 2024 | prnewswire.comArmata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial OfficerAugust 15, 2024 | markets.businessinsider.comBuy Rating Justified by Armata Pharmaceuticals’ Advancements in Bacteriophage Therapeutics and Strategic PartnershipsAugust 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Armata Pharmaceuticals Amid Positive Earnings and Promising Clinical ProgressSeptember 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.August 14, 2024 | finanznachrichten.deArmata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate UpdateAugust 13, 2024 | prnewswire.comArmata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate UpdateJuly 30, 2024 | prnewswire.comArmata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02July 28, 2024 | msn.comInnoviva’s (INVA) Stock Is Thriving With Strategic Investments Pay-OffJuly 11, 2024 | prnewswire.comArmata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa InfectionJuly 10, 2024 | prnewswire.comArmata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024May 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Armata Pharmaceuticals Amid Progress and Strategic Financial MovesMay 8, 2024 | finanznachrichten.deArmata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate UpdateMay 8, 2024 | investorplace.comARMP Stock Earnings: Armata Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024See More Headlines Receive ARMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Armata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNYSEAMERICAN:ARMP CUSIPN/A CIKN/A Webwww.armatapharma.com Phone(310) 655-2928Fax310-665-2963Employees70Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+200.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-69,040,000.00 Net Margins-1,693.47% Pretax Margin-1,802.72% Return on EquityN/A Return on Assets-64.34% Debt Debt-to-Equity RatioN/A Current Ratio0.25 Quick Ratio0.25 Sales & Book Value Annual Sales$4.53 million Price / Sales18.61 Cash FlowN/A Price / Cash FlowN/A Book Value($1.27) per share Price / Book-1.83Miscellaneous Outstanding Shares36,180,000Free Float5,242,000Market Cap$84.30 million OptionableNot Optionable Beta0.79 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Mina Pastagia M.D. (Age 49)MS, Chief Medical Officer Comp: $537.6kDr. Deborah L. Birx M.D. (Age 67)CEO & Director Mr. Richard Rychlik (Age 68)VP, Corporate Controller & Principal Financial Officer Mr. Peter HubbardVice President of OperationsDr. Pierre Kyme Ph.D.Senior Vice President of Business & Corporate DevelopmentKey CompetitorsSutro BiopharmaNASDAQ:STROElite PharmaceuticalsOTCMKTS:ELTPVoyager TherapeuticsNASDAQ:VYGRNeoleukin TherapeuticsNASDAQ:NLTXSNDLNASDAQ:SNDLView All Competitors ARMP Stock Analysis - Frequently Asked Questions How were Armata Pharmaceuticals' earnings last quarter? Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) released its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.52) by $0.13. Who are Armata Pharmaceuticals' major shareholders? Top institutional investors of Armata Pharmaceuticals include Concourse Financial Group Securities Inc.. View institutional ownership trends. How do I buy shares of Armata Pharmaceuticals? Shares of ARMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Armata Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Armata Pharmaceuticals investors own include VBI Vaccines (VBIV), Vaxart (VXRT), Amarin (AMRN), CRISPR Therapeutics (CRSP), Pfizer (PFE) and Micron Technology (MU). This page (NYSEAMERICAN:ARMP) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Armata Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Armata Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
